Cas:6163-58-2 Tri-o-tolylphosphine manufacturer & supplier

Chemical Name:Tri-o-tolylphosphine

CAS.NO:6163-58-2

Synonyms:Tri-o-tolylphosphine;Phosphine, tri-o-tolyl-;Phosphine, tris(2-methylphenyl)-;PHOSPHORUS TRI-O-TOLYL;TRI-2-TOLYLPHOSPHINE;tris(o-tolyl)phosphine;EINECS 228-193-9;tri(2-methylphenyl)phosphine;Tris(2-methylphenyl)phosphine;TRI-O-TOLYPHOSPHINE;tri-o-tolyl phopine;MFCD00008514;tri-ortho-toluyl-phosphine;Phosphine,tri-o-tolyl

Molecular Formula:C₂₁H₂₁P

Molecular Weight:304.365

HS Code:

Physical and Chemical Properties:

Melting point:123-125 °C(lit.)

Boiling point:412.4±44.0 °C at 760 mmHg

Density:N/A

Index of Refraction:

PSA:13.59000

Exact Mass:304.138092

LogP:7.07

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Tri-o-tolylphosphine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Phosphine,tri-o-tolyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tri-ortho-toluyl-phosphine Use and application,tri-ortho-toluyl-phosphine technical grade,usp/ep/jp grade.

Related News: Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women. Tri-o-tolylphosphine manufacturer At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. Tri-o-tolylphosphine supplier The drug, Imfinzi, when added to chemotherapy and the drugmaker��s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said. Tri-o-tolylphosphine vendor Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women. Tri-o-tolylphosphine factory Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women.